rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Although this mutation in KRAS accounts for 11% of all KRAS mutations in cancer, it is the most prominent KRAS mutant in lung cancer suggesting that G12C-specific inhibitors may provide a new approach for treating the subset of lung cancer patients harboring this mutant allele.
|
30366101 |
2019 |
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
We developed an integrative pharmacogenomics analysis to identify potential drug targets to overcome MEK/ERK inhibitor resistance in lung cancer cell lines with KRAS(G12C) mutation (n = 12).
|
31668570 |
2019 |
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Adding mTOR and IGF1R inhibitors to ARS-1620 greatly improves its effectiveness on KRAS-G12C mutant lung cancer cells in vitro and in mouse models.
|
31534020 |
2019 |
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S).
|
26920031 |
2016 |
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Next generation sequencing performed on the Ion Torrent platforms by the Ion Ampliseq Colon and Lung Cancer panel showed a similar genomic profile in both neoplastic sites with a concurrent KRAS G12C mutation.
|
25900221 |
2015 |
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Gene-expression profiles in lung cancer cell lines and surgically resected lung AC revealed that KRAS-G12C mutants had an epithelial to mesenchymal transition and a KRAS-independent phenotype.
|
25170638 |
2014 |
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Our study demonstrated that TRAIL significantly suppressed cell survival, by inducing apoptosis in a dose-dependent manner, in the pancreatic cancer BxPC-3 (wild type G12) and lung cancer A549 (G12S) cell lines.
|
20848283 |
2011 |
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
UNIPROT |
|
|
|
rs121913530
|
|
Carcinoma of lung
|
A |
0.880 |
CausalMutation
|
CLINVAR |
|
|
|
rs1051730
|
|
Carcinoma of lung
|
T |
0.800 |
GeneticVariation
|
GWASCAT |
Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk.
|
30104567 |
2018 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
In addition, the A alleles in CHRNA3 rs1051730 and CHRNA5 rs16969968 were associated with the risk for LC (OR = 1.66, P = 0.07 and OR = 1.57, P = 0.1, respectively) and for COPD (OR = 2.04, P = 0.01 and OR = 1.91, P = 0.02, respectively).
|
29993116 |
2018 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
As a result, 15 SNPs on or near 12 genes and one miRNA with strong evidence of association with lung cancer risk were identified, including TERT (rs2736098), CHRNA3 (rs1051730), AGPHD1 (rs8034191), CLPTM1L (rs401681 and rs402710), BAT3 (rs3117582), TRNAA (rs4324798), ERCC2 (Lys751Gln), miR-146a2 (rs2910164), CYP1B1 (Arg48Gly), GSTM1 (null/present), SOD2 (C47T), IL-10 (-592C/A and -819C/T), and TP53 (intron 6).
|
29110844 |
2017 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
The potential association of three polymorphisms in the CHRNA3 (rs1051730(G > A)), CHRNA5 (rs16969968(G > A)), and AGPHD1 (rs8034191(A > G)) with the lung cancer risk has been widely investigated, but the results are inconsistent.
|
27072204 |
2016 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
We observed a significant association between lung cancer and rs1051730 in pooled population by using allele (OR = 1.30, 95% CI = 1.27-1.34, P < 0.0001), dominant (OR = 1.41, 95% CI = 1.29-1.55, P < 0.0001), recessive (OR = 1.53, 95% CI = 1.42-1.65, P < 0.0001) and additive (OR = 1.75, 95% CI = 1.61-1.90, P < 0.0001) models.
|
26508385 |
2015 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
In conclusion, this meta-analysis demonstrated that the two common variations (rs8034191 and rs1051730) at 15q25 are a risk factor associated with increased LC susceptibility, but these associations vary in different ethnic populations.
|
24254305 |
2014 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
The nicotinic acetylcholine receptor polymorphism (rs1051730) on chromosome 15q25 is associated with major tobacco-related diseases in the general population with additional increased risk of COPD as well as lung cancer.
|
23061658 |
2012 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here, the authors apply a novel method for mediation analysis, allowing for gene-environment interaction, to a lung cancer case-control study (1992-2004) conducted at Massachusetts General Hospital using 2 single nucleotide polymorphisms, rs8034191 and rs1051730, on 15q25.1.
|
22306564 |
2012 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our findings demonstrated that CHRNA3 gene rs1051730-A allele and AGPHD1 gene rs8034191-T allele might be risk-conferring factors for the development of lung cancer in Caucasians, but not in East-Asians.
|
22701590 |
2012 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
The increase in cotinine levels indicated an increased risk of lung cancer with each additional copy of the rs1051730-rs16969968 risk allele (per-allele odds ratio = 1.31, 95% CI = 1.21 to 1.42).
|
22534784 |
2012 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
The CHRNA3 rs1051730 polymorphism has been associated to chronic obstructive pulmonary disease (COPD), lung cancer and nicotine dependence in case-control studies with high smoking exposure; however, its influence on lung function and COPD severity in the general population is largely unknown.
|
22441734 |
2012 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
We also investigated the relationship between the rs1051730 SNP in an intron of the CHRNA3 gene (the polymorphism most significantly associated with lung cancer risk and smoking behavior) and TSD.
|
21645942 |
2011 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
We found that 2 risk single nucleotide polymorphisms reported in the lung cancer GWA studies-rs8034191: A>G and rs1051730: G>A, located in this 15q24-25.1 region-were not associated with risk of pancreatic cancer.
|
21697764 |
2011 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Similarly, neither CHRNA3 rs8034191 nor rs1051730 were associated with lung cancer risk.
|
20068085 |
2010 |
rs1051730
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
We further showed that these two genetic variants on 15q24-25.1 independently influence lung cancer risk (rs1051730: P = 4.42 x 10(-11); OR, 1.60; 95% CI, 1.46-1.74; rs481134: P = 7.01 x 10(-4); OR, 0.81; 95% CI, 0.72-0.92).
|
20395203 |
2010 |